keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis c genotype 4

keyword
https://www.readbyqxmd.com/read/28238958/real-world-effectiveness-and-safety-of-oral-combination-antiviral-therapy-for-hepatitis-c-virus-genotype-4-infection
#1
Javier Crespo, Jose Luis Calleja, Inmaculada Fernández, Begoña Sacristan, Belén Ruiz-Antorán, Javier Ampuero, Marta Hernández-Conde, Javier García-Samaniego, Francisco Gea, Maria Buti, Joaquin Cabezas, Sabela Lens, Rosa Maria Morillas, Jose Ramon Salcines, Juan Manuel Pascasio, Juan Turnes, Federico Sáez-Royuela, Juan Arenas, Diego Rincón, Martin Prieto, Francisco Jorquera, Juan Jose Sanchez Ruano, Carmen A Navascués, Esther Molina, Adolfo Gallego Moya, José Maria Moreno-Planas
No abstract text is available yet for this article.
February 23, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28231665/-prognosis-and-related-risk-factors-for-465-subjects-infected-with-hepatitis-c-virus-in-danyang-jiangsu-province
#2
K Xu, C C Bao, J Wang, L G Zhu, J F Xu, H Peng, X J Zhai
Objective: To investigate the clinical features and viral load of persons infected with HCV and the risk factors for severe outcomes. Methods: Medical testing and questionnaire survey were conducted on 465 cases who were infected with HCV, 20-30 years back. HCV RNA, alanine transaminase (ALT), aspartate transaminase (AST), albumin, globulin and bilirubin were tested for these subjects. Factors as demography, tobacco and alcohol consumption, SNP of rs7453920 and rs2856718 on HLA-DQ gene of subjects with HCV RNA, were analyzed by multiple logistic regression method to explore the risk factors for severe outcomes among the patients...
February 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28231271/applying-antibody-sensitive-hypervariable-region-1-deleted-hepatitis-c-virus-to-the-study-of-escape-pathways-of-neutralizing-human-monoclonal-antibody-ar5a
#3
Rodrigo Velázquez-Moctezuma, Mansun Law, Jens Bukh, Jannick Prentoe
Hepatitis C virus (HCV) is a major cause of end-stage liver diseases. With 3-4 million new HCV infections yearly, a vaccine is urgently needed. A better understanding of virus escape from neutralizing antibodies and their corresponding epitopes are important for this effort. However, for viral isolates with high antibody resistance, or antibodies with moderate potency, it remains challenging to induce escape mutations in vitro. Here, as proof-of-concept, we used antibody-sensitive HVR1-deleted (ΔHVR1) viruses to generate escape mutants for a human monoclonal antibody, AR5A, targeting a rare cross-genotype conserved epitope...
February 23, 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28225575/25-hydroxy-vitamin-d-suppresses-hepatitis-c-virus-replication-and-contributes-to-rapid-virological-response-of-treatment-efficacy
#4
Jee-Fu Huang, Yu-Min Ko, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Ching-I Huang, Hua-Ling Yang, Shu-Chi Wang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang
AIM: 25-hydroxy vitamin D (Vit D) plays a role in treatment outcomes in chronic hepatitis C virus (HCV) infection (CHC). We aimed to clarify HCV replication is inhibited by Vit D in HCV replicon cells. Clinical implication was assessed for rapid virological response (RVR) and sustained virological response (SVR) among those patients receiving anti-viral therapy. METHODS: Cell survival and viral loads were observed in Con1 (genotype-1b) and J6/JFH (genotype-2a) cells treated with different doses of Vit D...
February 22, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28224470/three-patients-treated-with-sofosbuvir-plus-ledipasvir-for-recurrent-hepatitis-c-after-liver-transplantation
#5
Tomokazu Kawaoka, Michio Imamura, Kei Morio, Yuki Nakamura, Masataka Tsuge, Clair Nelson Hayes, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Hideki Ohdan, Kazuaki Chayama
We previously reported results of interferon (IFN)-free daclatasvir and asunaprevir for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT). Here we report three patients who achieved viral response with no effect on the blood concentrations of immunosuppressive agents following sofosbuvir plus ledipasvir treatment. The first patient was a 68-year-old female with HCV-related liver cirrhosis who failed to respond to pegylated-IFN and ribavirin (PEG-IFN/RBV) after living donor LT...
February 21, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28224025/lack-of-association-between-interleukin-28b-gene-polymorphisms-rs8099917g-t-rs12979860-c-t-and-susceptibility-to-chronic-hepatitis-c-virus-infection-tehran-iran
#6
Maryam Karkhane, Seyed Reza Mohebbi, Pedram Azimzadeh, Mahsa Saeedi Niasar, Mohamad Reza Sarbazi, Afsaneh Sharifian, Afshin Mohammad Alizadeh
AIM: Chronic Hepatitis C infection is a critical health problem worldwide, which caused by hepatitis C virus (HCV). Interleukin 28B (IL28B) is a determinant factor in disease progression and also susceptibility to chronic HCV infection. BACKGROUND: The most significant aim of this study is to analyze the association between IL28B gene polymorphisms with susceptibility to chronic HCV infection in Iranian population. METHODS: This study follows a case- control study design, in which, 288 patients with chronic hepatitis C and 250 healthy individuals were genotyped for IL28B polymorphisms (rs12979860 C/T and rs8099917 G/T)...
December 2016: Gastroenterology and Hepatology From Bed to Bench
https://www.readbyqxmd.com/read/28219761/development-and-validation-of-a-real-time-reverse-transcription-pcr-assay-for-rapid-and-low-cost-genotyping-of-hepatitis-c-virus-genotypes-1a-1b-2-and-3a
#7
Andrea D Olmstead, Tracy D Lee, Ron Chow, Kingsley Gunadasa, Brian Auk, Mel Krajden, Agatha N Jassem
Hepatitis C virus (HCV) infection affects millions of people and leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Treatment regimen selection requires HCV genotype (Gt) and Gt 1 subtype determination. Use of a laboratory developed, reverse transcription (RT)-PCR assay was explored as a low-cost, high-throughput screening approach for the major HCV genotypes and subtypes in North America. A commercial line probe assay (LiPA) was used for comparison. Sequencing and/or an alternative PCR assay were used for discordant analyses...
February 17, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28217256/interferon-free-regimens-in-patients-with-hepatitis-c-infection-and-renal-dysfunction-or-kidney-transplantation
#8
REVIEW
Evangelos Cholongitas, Chrysoula Pipili, George V Papatheodoridis
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several current regimens, is officially contraindicated. Given that ribavirin free regimens are preferable in CKD, elbasvir/grazoprevir is offered in CHC patients with genotype 1 or 4 and ombitasvir/paritaprevir and dasabuvir in genotype 1b for 12 wk. Although regimens containing peginterferon with or without ribavirin are officially recommended for patients with CKD and genotype 2, 3, 5, 6, such regimens are rarely used because of their low efficacy and the poor safety and tolerance profile...
February 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28213381/outcomes-of-treatment-with-direct-acting-antivirals-for-infection-with-hepatitis-c-virus-genotypes-1-4-in-an-ambulatory-care-setting
#9
Timothy A Bach, Kathy Zaiken
PURPOSE: Outcomes with direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) genotypes 1-4 were determined. METHODS: A total of 360 patients at 36 clinical sites in Massachusetts with HCV genotypes 1-4 and a prescription for at least one DAA medication between May 2011 and October 2015 were included. The primary investigator completed a retrospective and concurrent chart review, and data were collected through April 2016. RESULTS: A total of 446 patients were assessed for eligibility into the study, with 86 patients excluded...
March 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28211229/serum-micrornas-as-predictors-for-liver-fibrosis-staging-in-hepatitis-c-virus-associated-chronic-liver-disease-patients
#10
Olfat G Shaker, Mahmoud A Senousy
Accurate staging of liver fibrosis is important for clinical decision making and personalized management. Liver fibrosis is influenced by patients' genomics, including IFNL3 genotype and microRNA expression. However, incorporating microRNAs into fibrosis prediction algorithms has not been investigated. We examined the potential of 8 selected serum microRNAs; miR-122, miR-126, miR-129, miR-199a, miR-155, miR-203a, miR-221, and miR-223 as non-invasive biomarkers to stage liver fibrosis in HCV-associated chronic liver disease (HCV-CLD)...
February 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28202801/molecular-epidemiology-and-strain-comparison-between-hepatitis-e-virus-in-human-sera-and-pig-livers-during-2014-2016-in-hong-kong
#11
Martin C W Chan, Kirsty Kwok, Tin-Nok Hung, Paul K S Chan
Hepatitis E virus (HEV) causes substantial morbidity and mortality in developing countries and is considered an emerging food-borne pathogen in previously non-endemic developed countries. To investigate genetic association between human HEV infection and HEV-contaminated high-risk food in Hong Kong, we compared local virus strains obtained from hepatitis E patient sera with those surveyed from high-risk food items during 2014-2016. Twenty-four cases of laboratory-confirmed human HEV infections were identified from January 2014 to March 2016 in our hospitals...
February 15, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28202798/high-prevalence-and-diversity-of-hepatitis-viruses-in-suspected-cases-of-yellow-fever-in-the-democratic-republic-of-congo
#12
Sheila Makiala-Mandanda, Frédéric Le Gal, Nadine Ngwaka-Matsung, Steve Ahuka-Mundeke, Richard Onanga, Berthold Bivigou-Mboumba, Elisabeth Pukuta-Simbu, Athenaïs Gerber, Jessica L Abbate, Dieudonné Mwamba, Nicolas Berthet, Eric Maurice Leroy, Jean-Jacques Muyembe-Tamfum, Pierre Becquart
The majority of patients with acute febrile jaundice (>95%) identified through a yellow fever surveillance program in the Democratic Republic of Congo (DRC) test negative for antibodies against yellow fever virus. However, no etiological investigation has ever been carried out on these patients. Here, we tested for hepatitis A (HAV), B (HBV), C (HCV), D (HDV) and E (HEV) viruses, all of which can cause acute febrile jaundice, in patients included in the yellow fever surveillance program in the DRC. On a total of 498 serum samples collected from suspected cases of yellow fever from January 2003 to January 2012, ELISA techniques were used to screen for antibodies against HAV (IgM) and HEV (IgM) and for antigens and antibodies against HBV (HBsAg and anti-HBc IgM), HCV and HDV...
February 15, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28197802/effects-of-vaccine-acquired-polyclonal-anti-hbs-antibodies-on-the-prevention-of-hbv-infection-of-non-vaccine-genotypes
#13
Masaki Kato, Susumu Hamada-Tsutsumi, Chiaki Okuse, Aiko Sakai, Nobuyuki Matsumoto, Masaaki Sato, Toshiyuki Sato, Mitsumi Arito, Kazuki Omoteyama, Naoya Suematsu, Kazuki Okamoto, Takanobu Kato, Fumio Itoh, Ryo Sumazaki, Yasuhito Tanaka, Hiroshi Yotsuyanagi, Tomohiro Kato, Manae Suzuki Kurokawa
BACKGROUND: In universal hepatitis B (HB) vaccination, single vaccine-derived polyclonal anti-HBs antibodies (anti-HBs) need to inhibit infection of HB viruses (HBV) of non-vaccine genotypes. We experimentally addressed this issue. METHODS: Anti-HBs-positive sera were obtained by vaccination with genotype A- or C-derived HBs antigen (HBsAg, gtA-sera or gtC-sera). Their reactivity to genotype A- and C-derived HBsAg (gtA-Ag and gtC-Ag) was measured by ELISA. The capacity of sera to neutralize HBV was evaluated using an in vitro infection model...
February 14, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28195877/direct-acting-antivirals-are-effective-for-chronic-hepatitis-c-treatment-in-elderly-patients-a-real-world-study-of-17%C3%A2-487-patients
#14
Feng Su, Lauren A Beste, Pamela K Green, Kristin Berry, George N Ioannou
BACKGROUND: The mean age of patients with chronic hepatitis C virus (HCV) infection in the USA has been increasing. Despite the increasing proportion of HCV-infected elderly patients, this group is under-represented in clinical trials of HCV treatment. AIM: We aimed to describe the real-world effectiveness of direct-acting antivirals (DAAs) among elderly patients. PATIENTS AND METHODS: We retrospectively identified 17 487 HCV-infected patients who were started on treatment with sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir-based regimens in the Veterans Affairs Healthcare System between 1 January 2014 and 30 June 2015...
February 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28193664/in-vitro-antiviral-activity-and-resistance-profile-of-the-next-generation-hepatitis-c-virus-ns5a-inhibitor-pibrentasvir
#15
Teresa I Ng, Preethi Krishnan, Tami Pilot-Matias, Warren Kati, Gretja Schnell, Jill Beyer, Thomas Reisch, Liangjun Lu, Tatyana Dekhtyar, Michelle Irvin, Rakesh Tripathi, Clarence Maring, John T Randolph, Rolf Wagner, Christine Collins
Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with 50% effective concentration (EC50)values ranging from 1.4 to 5.0 picomolar (pM) against HCV replicons containing NS5A from genotypes 1 to 6. Pibrentasvir demonstrated similar activity against a panel of chimeric replicons containing HCV genotype 1 to 6 NS5A from clinical samples. Resistance selection studies were conducted using HCV replicon cells with NS5A from genotype 1a, 1b, 2a, 2b, 3a, 4a, 5a or 6a at pibrentasvir concentration of 10- or 100-fold over its EC50 values for the respective replicons...
February 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28193518/safety-and-efficacy-of-elbasvir-grazoprevir-in-patients-with-hepatitis-c-virus-infection-and-compensated-cirrhosis-an-integrated-analysis
#16
Ira M Jacobson, Eric Lawitz, Paul Y Kwo, Christophe Hézode, Cheng-Yuan Peng, Anita Y M Howe, Peggy Hwang, Janice Wahl, Michael Robertson, Eliav Barr, Barbara A Haber
BACKGROUND & AIMS: Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials. METHODS: We performed an integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials...
February 10, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28192235/high-hcv-subtype-heterogeneity-in-a-chronically-infected-general-population-revealed-by-high-resolution-hcv-subtyping
#17
Francisco Rodriguez-Frias, Leonardo Nieto, Josep Gregori, Damir Garcia-Cehic, Rosario Casillas, David Tabernero, Maria Homs, Maria Blasi, Marta Vila, Qian Chen, Victor Vargas, Lluís Castells, Lluís Viladomiu, Joan Genesca, Beatriz Minguez, Salvador Augustin, Judit Carbonell, Celia Perales, Maria Eugenia Soria, Miriam Asensio, Meritxell Llorens, Laura Ordeig, Cristina Godoy, Maria Buti, Rafael Esteban, Tomas Pumarola, Juan Ignacio Esteban, Josep Quer
OBJECTIVES: Accurately characterize the chronically-infected general HCV population in the Barcelona area by a highly sensitive subtyping method able to identify the 67 recognized hepatitis C virus (HCV) subtypes, and to discriminate mixed infections in a single individual. This information has strong implications on patient management, in deciding the optimal combination of direct-acting antivirals (DAAs) for each patient. METHODS: HCV subtyping by UDPS. All HCV patients who attended Vall d'Hebron Hospital outpatient clinics from February 2015 to May 2016 (N=1473) were included...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28191658/interpatient-mutational-spectrum-of-human-coronavirus-oc43-revealed-by-illumina-sequencing
#18
Geoffrey J Gorse, Gira B Patel, Xiaofeng Fan
Human coronaviruses (HCoV) are RNA viruses that cause respiratory tract infections with viral replication of limited duration. The host and viral population heterogeneity could influence clinical phenotypes. Employing long RT-PCR with Illumina sequencing, we quantified the gene mutation load at 0.5% mutation frequency for the 4,529 bp-domain spanning the Spike gene (4,086 bp) of HCoV-OC43 in four upper respiratory clinical specimens obtained during acute illness. There were a total of 121 mutations for all four HCoV samples with the average number of mutations at 30...
February 12, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28191540/hepatitis-c-in-cameroon-what-is-the-progress-from-2001-to-2016
#19
Borris Rosnay Tietcheu Galani, Richard Njouom, Paul Fewou Moundipa
Chronic hepatitis C is a major public health problem in sub-Saharan countries and particularly in Cameroon where the prevalence rate is around 7.6% in the age group of 55-59 years. Recent investigations into this infection allowed defining a national seroprevalence, characterizing virological and biological profiles of infected patients and identifying medicinal plants of potential interest in hepatitis C therapy. However, in Cameroon, no existing report currently presents a good overview of hepatitis C research in relation to these parameters...
December 1, 2016: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28187879/validated-stability-indicating-hplc-dad-method-for-determination-of-the-recently-approved-hepatitis-c-antiviral-agent-daclatasvir
#20
M M Baker, D S El-Kafrawy, M S Mahrous, T S Belal
A comprehensive stability indicating HPLC with diode array detection method was developed for the determination of the recently approved antiviral drug daclatasvir dihydrochloride (DCV) which is used for the treatment of chronic Hepatitis C Virus (HCV) genotype 3 infection. Effective chromatographic separation was achieved using Waters C8 column (4.6×250mm, 5μm particle size) with isocratic elution of the mobile phase composed of mixed phosphate buffer pH 2.5 and acetonitrile in the ratio of 75:25 (by volume)...
February 7, 2017: Annales Pharmaceutiques Françaises
keyword
keyword
86765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"